Skip to main content
. 2019 Dec 6;38(5):462–471. doi: 10.1200/JCO.19.01814

FIG 3.

FIG 3.

(A) Overall survival (OS) of patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 2+ and IHC3+ tumors. (B) HER3 and (C) growth factor–binding protein 7 (Grb7) expression at 10× magnification. (D) Treatment response by Mandard score in patients with Grb7-positive and -negative tumors.